Early Decline in Serum Phospho-Cse1l Levels in Vemurafenib/Sunitinib-Treated Melanoma and Sorafenib/Lapatinib-Treated Colorectal Tumor Xenografts

Journal of Translational Medicine - United Kingdom
doi 10.1186/s12967-015-0553-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib

Clinical Genitourinary Cancer
OncologyUrology
2012English

Magnetic Resonance Imaging Identifies Early Effects of Sunitinib Treatment in Human Melanoma Xenografts

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2013English

Hypothyroidism Side Effect in Patients Treated With Sunitinib or Sorafenib: Clinical and Structural Analyses

PLoS ONE
Multidisciplinary
2016English

High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated With Sorafenib

Clinical Cancer Research
Cancer ResearchOncology
2015English

Multiple White Cysts on Face and Trunk of a Melanoma Patient Treated With Vemurafenib

Acta Dermato-Venereologica
DermatologyMedicine
2015English

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Conjunctival Melanoma in a Horse Treated by Tumor Resection and Cryotherapy

Acta Scientiae Veterinariae
Veterinary
2018English

Cancer Patients Treated With Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

Clinical Cancer Research
Cancer ResearchOncology
2011English

Long-Term Outcome in BRAFV600E Melanoma Patients Treated With Vemurafenib: Patterns of Disease Progression and Clinical Management of Limited Progression

European Journal of Cancer
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy